The number of new Covid-19 cases in the United States last week rose 24% to more than 485,000 while the number of tests performed rose 5.5%, according to a Reuters analysis of state and county reports.
The United States saw the country’s highest-ever number of new Covid-19 cases in the past two days, keeping the pandemic a top election issue as Vice President Mike Pence travels the U.S. to campaign despite close aides testing positive.
The number of new Covid-19 cases in the United States last week rose 13% to more than 393,000, approaching levels last seen during the summer peak, according to a Reuters analysis.
The number of novel coronavirus cases in the United States topped 7 million – more than 20% of the world’s total – as Midwest states reported spikes in Covid-19 infections in September, according to a Reuters tally.
New Jersey Governor Phil Murphy said he would sign an executive order requiring people to wear face coverings outdoors to prevent a resurgence of the novel coronavirus whenever social distancing is not possible.
The U.S. coronavirus outbreak crossed a grim milestone of over 3 million confirmed cases as more states reported record numbers of new infections, and Florida faced an impending shortage of intensive care unit hospital beds.
Rising coronavirus cases in 39 U.S. states cast a shadow over the nation’s Fourth of July celebrations as health experts worried that holiday parties will cause a further spike in infections that could overwhelm hospitals.
The U.S. death toll from the novel coronavirus rose to more than 40,000 on Sunday, the highest in the world and almost double the number of deaths in the next highest country Italy, according to a Reuters tally.
As a critical industry during the COVID-19 pandemic, biopharma companies are expected to remain in operation – but with a skeleton staff. Anticipating stay-at-home mandates, life sciences companies and labs in especially hard-hit regions had already begun preparing.
U.S. state attorneys general said Johnson & Johnson and a company unit agreed to pay nearly $117 million to settle litigation over deceptive marketing of transvaginal surgical mesh devices.
